| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Agren, B, et al.
(författare)
-
MR imaging of multiple myeloma patients with bone-marrow transplants
- 1998
-
Ingår i: Acta radiologica (Stockholm, Sweden : 1987). - : SAGE Publications. - 0284-1851 .- 1600-0455. ; 39:1, s. 36-42
-
Tidskriftsartikel (refereegranskat)abstract
- Purpose: to evaluate the role of MR imaging in the examination of multiple myeloma (MM) patients with bone-marrow transplants Material and Methods: A total of 40 MR examinations were made of 20 patients: 33 examinations of the spine and pelvis in 20/20 patients; and 7 examinations of the femora in 5/20 patients. the 40 examinations were evaluated and the results compared with those found at radiography. Altogether 13/20 patients were re-examined: 10 after 1 year (1 patient twice); and 3 after 2 years. Five sequences were tested, 3 of them first without and then with i.v. contrast enhancement Results: in 24/33 examinations, active MM lesions were shown by MR. in 16/33 examinations, MR showed greater spread and detectability than radiography. in the 5/20 femoral patients, 3 had a peripheral red bone-marrow extension in the femora. in the 13 re-examinations, the lesions had spread in 4 patients, were unchanged in 7, and had decreased in 2. the lesions were easier to detect with the turbo inversion recovery (TIR) technique and with fat saturation than with the conventional spin-echo sequences. Contrast enhancement made the lesions more conspicuous in 8/17 examinations Conclusion: MR has the potential to be a useful routine examination with T1-weighted and TIR sequences of selected areas, and without the use of contrast enhancement. However, further longitudinal studies are necessary in order to evaluate its possible predictive value
|
|
| 6. |
|
|
| 7. |
- Ekholm, S, et al.
(författare)
-
Tolerance and efficacy of Omniscan (gadodiamide injection) in MR imaging of the central nervous system
- 1996
-
Ingår i: Acta Radiologica. - 1600-0455. ; 37:2, s. 223-228
-
Tidskriftsartikel (refereegranskat)abstract
- PURPOSE: This Swedish multicenter trial was performed on patients with known or suspected lesions of the CNS for which an MR examination using a contrast medium was indicated. A total of 8 MR centers participated in the study to establish the safety and efficacy of Omniscan (gadodiamide injection) in clinical routine using a standard dose of 0.1 mmol Gd/kg b.w. MATERIAL AND METHODS: Seven hundred adult patients who had been referred for MR investigation of suspected CNS lesions were included in the study. Since most patients were examined on an outpatient basis, it was decided to use an explicit questionnaire regarding adverse events that developed within 24 h after examination. The efficacy evaluation involved comparisons of detectability, delineation, and number of lesions before and after injection of Omniscan. RESULTS: No serious or unexpected adverse event was found. There were a total of 70 (10.2%) patients with adverse events, excluding those judged not to be contrast media-related. However, only 15 patients (2.2%) had adverse events that possibly or probably were related to the contrast medium. Usually, the symptoms were headache, dizziness, abnormal taste, and nausea. Two patients complained of itching, but only one developed urticaria. The efficacy was similar to that of other currently used Gd-based MR agents. Lesions were more often seen on T2-weighted images, but the contrast medium improved lesion delineation, contributing to higher certainty in diagnosis, and provided more confidence in excluding suspected abnormality. CONCLUSION: Omniscan was found to be a safe and clinically valuable contrast medium for MR imaging of the CNS.
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
|
|
